A provider-neutral 100-point scorecard for evaluating licensing, evidence, diagnostics, follow-up, pricing and records before paying a longevity clinic.
A reassessment of 2025 longevity milestones by evidence type: investment, infrastructure, research frameworks, competitions, and the clinical conclusions none of them support yet.
The Nature Metabolism review found sparse human tissue data and limited clinical efficacy. Three 2026 studies add narrow signals, but do not establish NAD+ interventions as general longevity treatments.
The Atlantic raises valid questions about screening, peptides, off-label drugs, and compounded products. We checked those points against FDA and radiology guidance.
